

# Systematic review of health state utility values used in European pharmacoeconomic evaluations for chronic hepatitis C: impact on cost-effectiveness results

## Applied Health Economics and Health Policy

Ru Han<sup>1,2\*</sup>, Clément François<sup>1,2</sup>, Mondher Toumi<sup>1,2</sup>

<sup>1</sup>University of Aix-Marseille, Marseille, France;

<sup>2</sup>Creativ-Ceutical, Paris, France;

\*Corresponding author: [rha@creativ-ceutical.com](mailto:rha@creativ-ceutical.com)

Email address: [cfr@creativ-ceutical.com](mailto:cfr@creativ-ceutical.com); [mondher.TOUMI@univ-amu.fr](mailto:mondher.TOUMI@univ-amu.fr);

Address: 215, rue de Faubourg St-Honoré 75008 Paris

## Supplementary file 1.1 Search strategy for studies in Medline and Embase via Ovid

ID	Category	Search terms	Hits	
#1	Population	exp "hepatitis C"/	174,360	
#2		("Hepatitis C virus" or "Hepatitis C viruses").mp.	139,498	
#3		HCV.mp.	150,571	
#4		Hepaciviruses.mp.	165	
#5		("Hepatitis C-Like Viruses" or "Hepatitis C-Like Virus" or "Hepatitis C Like Viruses" ) .mp.	31	
#6		or/1-5	246,721	
#7		Intervention	("treatment" or "treating" or "drug" or "pharmaceutical").mp.	22,240,160
#8			("interferon" or "IFN" or "ribavirin").mp.	633,951
#9			("sofosbuvir" or "daclatasvir" or "ledipasvir" or "paritaprevir" or "ombitasvir" or "ritonavir" or "dasabuvir" or "velpatasvir" or "voxilaprevir" or "grazoprevir" or "glecaprevir" or "pibrentasvir").mp.	45,008
#10			or/ 7-9	22,468,153
#11	Model	model*.mp.	8,167,108	
#12	Evaluation type	exp "cost utility analysis"/ or exp "cost benefit analysis"/ or exp "cost minimization analysis"/ or exp "cost"/ or exp "cost effectiveness analysis"/	730,337	
#13		exp health economics/	817,066	
#14		("cost analysis" or cost-analysis or cost analyses or cost-analyses).mp.	67,047	
#15		("cost effective*" or cost-effective*).mp.	364,353	
#16		("cost benefit*" or cost-benefit*).mp.	173,613	
#17		("cost consequence*" or cost-consequence*).mp.	1,408	
#18		("cost utility" or cost-utility).mp.	15,619	
#19		("cost minimization" or cost-minimization or "cost minimisation" or cost-minimisation).mp.	5,386	
#20		cost*.mp.	1,675,936	
#21		economic*.mp.	1,288,336	
#22	(pharmacoeconomic* or pharmaco-economic*).mp.	90,581		
#23	or/12-22	2,762,485		
#24	Final	6 and 10 and 11 and 23	2,790	
#25		limit 24 to yr="2017-Current"	923	

## Supplementary file 1.2. Inclusion/exclusion criteria

Criteria elements	Inclusion criteria	Exclusion criteria
<b>Population</b>	Adult patients (aged 18 years) with chronic hepatitis C	None
<b>Intervention</b>	All treatment strategies including DAAs and interferon	Prevention, screening and diagnosis strategies
<b>Comparator</b>	No treatment or with other treatment strategies	None
<b>Outcomes of interest</b>	Elicited utility weights	None
<b>Study</b>	Model-based pharmacoeconomic evaluation	Budget impact analysis, cost-of-illness analysis or clinical trial
<b>Publication timeframe</b>	Published after 2017 to the present	None
<b>Geographical scope</b>	Economic studies conducted in European countries	Reporting data on non-European countries only
<b>Language</b>	English language	The other languages

## Supplementary file1.3. Framework of quality assessment of HSUVs used in CUAs

Domain	Criteria	Scores and description		
Identification of source	Systematic review	0	1	2
		No source and value of HSUVs reported	Source reported but not identified through systematic review	Systematic review conducted to identify the relevant HSUVs
	Sensitivity analysis	0	1	2
		No sensitivity analysis or scenario analysis of HSUVs and justification	Sensitivity analysis conducted but no range and source of HSUVs reported	Sensitivity analysis conducted with source reported
Methodological quality	Elicitation method	0	1	2
		No description of elicitation method for HSUVs and choice of method	Description for one or more HSUVs but not for all or no choice of method	Complete description of each HSUV provided and choice of method
	Responder	0	1	2
		No description of responder (characteristic, size and nationality)	Partial description of responder and choice of responder	Complete description of responder and choice of responder
Appropriate application	Population comparability	0	1	2
		Different population (diagnosis, severity and risk groups) and country without reasonable explanation	Different population and county between CUAs and elicitation studies with reasonable explanation	The same population and country in CUAs as in utility elicitation studies
	Health states comparability	0	1	2
		Different health states and HSUVs in the CUA without explanation	Different health states and HSUVs with explanation on derivation method	The same health states and HSUVs or with complete interpretation
	Discussion on proper use	0	1	2
		No discussion on the use of HSUVs by other researchers in CUAs	Incomplete discussion of limitations and use of HSUVs	Complete discussion of limitations and use of HSUVs

## Supplementary file1.4. Input of baseline characteristic, transition probability, efficacy and costs from Johnson 2016

Table 1 Baseline characteristics

Variable	Value	
	Treatment naïve	Treatment experienced
Age	40.0	45.0
Male	70.0%	70.0%
F0-F3 (Chronic HCV)	90.0%	68.0%
F4 (compensated cirrhosis)	10.0%	32.0%
Treatment experience	28.9%	71.1%

**Table 2 Transition probability**

Variable	Value
Chronic HCV to compensated cirrhosis	0.037
Chronic HCV to hepatocellular carcinoma	0.000
Compensated cirrhosis to decompensated cirrhosis	0.039
Compensated cirrhosis to hepatocellular carcinoma	0.014
Decompensated cirrhosis to hepatocellular carcinoma	0.014
Recovered without compensated cirrhosis to hepatocellular carcinoma	0.012
Recovered with compensated cirrhosis to hepatocellular carcinoma	0.012
Decompensated cirrhosis to liver transplant	0.020
Hepatocellular carcinoma to liver transplant	0.020
Decompensated cirrhosis to liver-related death	0.130
Liver transplant in the first year to liver-related death	0.150
Liver transplant in subsequent years to liver-related death	0.057
Hepatocellular carcinoma in the first year to liver-related death	0.427
Hepatocellular carcinoma in subsequent years to liver-related death	0.427
Viral reinfection	0.010
Spontaneous remission	0.000

**Table 3 Efficacy and safety**

Variable	Value in ODP	Value in PR
Treatment Naïve		
Chronic HCV	0.972	0.445
Compensated cirrhosis	0.963	0.333
Treatment experienced		
Chronic HCV	0.974	0.158
Compensated cirrhosis	0.972	0.143
Adverse events		
Any serious adverse events	0.20%	15.30%
Anemia	3.90%	19.40%
Rash	7.90%	24.40%
Depression	0.00%	21.90%

**Table 4 Costs**

Variable	Value
Annual health state-related costs	
Chronic HCV	£681
Compensated cirrhosis	£1,841
No HCV	£0
Recovered without compensated cirrhosis	£419
Recovered with compensated cirrhosis	£921
Decompensated cirrhosis	£14,755
Hepatocellular carcinoma in the first year	£13,148
Hepatocellular carcinoma in subsequent years	£13,148
Liver transplant in the first year	£59,518
Liver transplant in subsequent years	£2,241
Daily drug costs	
ODP	£429
PR	£34
Treatment monitoring costs per treatment course	

ODP	£661
PR	£1,127
Treatment costs of drug-related adverse events per event	
Any serious adverse events	£1,874
Anemia	£507
Rash	£168
Depression	£418

**Table 5 UK life table**

Age	Value (Males)	Value (Females)
18	0.00040	0.00021
19	0.00044	0.00020
20	0.00047	0.00020
21	0.00050	0.00021
22	0.00049	0.00020
23	0.00053	0.00023
24	0.00054	0.00022
25	0.00062	0.00024
26	0.00057	0.00027
27	0.00061	0.00028
28	0.00068	0.00031
29	0.00068	0.00033
30	0.00073	0.00038
31	0.00077	0.00040
32	0.00093	0.00048
33	0.00089	0.00050
34	0.00098	0.00051
35	0.00103	0.00059
36	0.00116	0.00066
37	0.00119	0.00073
38	0.00124	0.00073
39	0.00139	0.00084
40	0.00150	0.00093
41	0.00171	0.00098
42	0.00181	0.00108
43	0.00199	0.00114
44	0.00210	0.00129
45	0.00220	0.00144
46	0.00237	0.00153
47	0.00274	0.00166
48	0.00280	0.00178
49	0.00311	0.00192
50	0.00340	0.00214
51	0.00350	0.00235
52	0.00381	0.00258
53	0.00397	0.00281
54	0.00441	0.00301
55	0.00492	0.00329
56	0.00547	0.00361
57	0.00587	0.00386
58	0.00637	0.00423

59	0.00703	0.00476
60	0.00796	0.00517
61	0.00861	0.00562
62	0.00932	0.00628
63	0.01048	0.00686
64	0.01145	0.00732
65	0.01224	0.00788
66	0.01350	0.00888
67	0.01460	0.00961
68	0.01561	0.01035
69	0.01723	0.01152
70	0.01884	0.01267
71	0.02131	0.01424
72	0.02355	0.01589
73	0.02602	0.01793
74	0.02959	0.01967
75	0.03295	0.02224
76	0.03643	0.02546
77	0.03986	0.02746
78	0.04409	0.03139
79	0.04921	0.03462
80	0.05522	0.03968
81	0.06139	0.04462
82	0.06929	0.05108
83	0.07853	0.05843
84	0.08769	0.06669
85	0.09819	0.07496
86	0.10951	0.08545
87	0.12239	0.09645
88	0.13706	0.10996
89	0.15105	0.12363
90	0.16874	0.13939
91	0.18600	0.15458
92	0.20164	0.17162
93	0.22069	0.18837
94	0.24303	0.20957
95	0.26757	0.23369
96	0.28755	0.25312
97	0.30529	0.26823
98	0.31356	0.28397
99	0.34860	0.31482
100	0.38566	0.34091

---